Profile

My major area of research interest is the design and conduct of multi-center renal clinical trials where I have had leadership roles in numerous NIH sponsored clinical trials including the MDRD, AASK, HEMO, pilot Diabetic Nephropathy Trial and currently the SPRINT Trial.  In these trials, in addition to being the PI at the Vanderbilt high enrolling and high performing center I have also had numerous leadership roles for the overall trial including serving on or leading the protocol design, form design, intervention, htn management, outcome classification and publication committees.  I have played a key roles in the Collaborative Study Group(CSG), an independent ARO, sitting  on its executive committee for twenty years in charge of protocol development and more recently as Vice President . The CSG has been responsible for key clinical trials in nephrology leading to FDA approval of captopril and irbessrtan for diabetic nephropathy. More recently I have led the clinical coordinating center, developed the protocol, forms and other key trial elements for the development of a novel phosphate binder the results if which have been submitted to the FDA.

Currently, I serve as head of several NIH and industry sponsored oversight /advisory panels for other studies and I sit on the cardio-renal FDA Advisory Board for a six year term.

In my academic role I have over 200 publications in peer approved journals and I am the director of the renal fellowship training program at Vanderbilt.

 

Publications

The following timeline graph is generated from all co-authored publications.

  1. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, Shahinfar S, Lewis JB, Lambers Heerspink HJ (2012) Am J Kidney Dis 59(1): 75-83
    › Primary publication · 22051245 (PubMed)
  2. Pyridorin in type 2 diabetic nephropathy. Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK, Lewis JB, Collaborative Study Group (2012) J Am Soc Nephrol 23(1): 131-6
    › Primary publication · 22034637 (PubMed) · PMC3269925 (PubMed Central)
  3. Systems involving hydrogenated and fluorinated chains: volumetric properties of perfluoroalkanes and perfluoroalkylalkane surfactants. Morgado P, Lewis JB, Laginhas CM, Martins LF, McCabe C, Blas FJ, Filipe EJ (2011) J Phys Chem B 115(50): 15013-23
    › Primary publication · 21950377 (PubMed)
  4. Membranous nephropathy with crescents. Basford AW, Lewis J, Dwyer JP, Fogo AB (2011) J Am Soc Nephrol 22(10): 1804-8
    › Primary publication · 21903992 (PubMed)
  5. Chronic idiopathic neutrophilia: experience and recommendations. Weir AB, Lewis JB, Arteta-Bulos R (2011) South Med J 104(7): 499-504
    › Primary publication · 21886049 (PubMed)
  6. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I, Collaborative Study Group (2011) Am J Kidney Dis 58(5): 729-36
    › Primary publication · 21872376 (PubMed)
  7. A framework for evaluating the appropriateness of clinical decision support alerts and responses. McCoy AB, Waitman LR, Lewis JB, Wright JA, Choma DP, Miller RA, Peterson JF (2012) J Am Med Inform Assoc 19(3): 346-52
    › Primary publication · 21849334 (PubMed) · PMC3341775 (PubMed Central)
  8. Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Hans-Henrik P (2012) J Renin Angiotensin Aldosterone Syst 13(1): 118-21
    › Primary publication · 21824990 (PubMed)
  9. Olmesartan to prevent the development of microalbuminuria: is it new? Is it true? Is it important? Dwyer JP, Lewis JB (2011) Am J Kidney Dis 58(5): 700-3
    › Primary publication · 21802806 (PubMed)
  10. Viscosity of liquid perfluoroalkanes and perfluoroalkylalkane surfactants. Morgado P, Laginhas CM, Lewis JB, McCabe C, Martins LF, Filipe EJ (2011) J Phys Chem B 115(29): 9130-9
    › Primary publication · 21634410 (PubMed)